Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia 15Leukemia, Lymphocytic, Chronic, B-Cell 10Lymphoma 9Myelodysplastic Syndromes 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Lymphoma, Non-Hodgkin 6Hodgkin Disease 6Multiple Myeloma 5Myeloproliferative Disorders 4Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Graft vs Host Disease 4Neoplasms, Plasma Cell 3Lymphoma, Mantle-Cell 3Lymphoma, Follicular 3Leukemia, Myeloid, Chronic-Phase 3Leukemia, Myeloid, Acute 3Hematologic Neoplasms 3Congenital Abnormalities 3Myelodysplastic-Myeloproliferative Diseases 2Lymphoma, T-Cell 2Lymphoma, Large B-Cell, Diffuse 2Leukemia, Myeloid, Accelerated Phase 2Hematologic Diseases 2Blast Crisis 2Anemia, Aplastic 2Waldenstrom Macroglobulinemia 1Unrecognized Condition: Mature B or T-cell Neoplasm 1Thrombocythemia, Essential 1Thalassemia 1Primary Myelofibrosis 1

Interventions

Gemcitabine 34pembrolizumab 27Paclitaxel 21Cyclophosphamide 21Docetaxel 20Carboplatin 20Irinotecan 19Capecitabine 19Fluorouracil 17Bevacizumab 15Dexamethasone 14fludarabine 13Oxaliplatin 13Leucovorin 13Blood Specimen Collection 13Everolimus 12Cetuximab 12Ipilimumab 11Erlotinib Hydrochloride 11Rituximab 10Pemetrexed 10Cisplatin 10venetoclax 9Temozolomide 9Sunitinib 9Nivolumab 9Trastuzumab 8Interleukin-2 8aldesleukin 7Epoetin Alfa 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Neoplasms × Alemtuzumab × Clear all
NCT00983528 2020-08-12

Alemtuzumab and Clofarabine for Relapsed or Refractory Acute Lymphoblastic Leukemia

University of California, San Diego

Phase 1/2 Terminated
6 enrolled 6 charts
LymphoidOther hematologic neoplasm

Leukemia, Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡